Clinical trial
A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet
NCT02395172 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 24, 2015
- Completion date
- December 3, 2019
- Enrollment
- 792 (actual)
- Sites
- 260
Conditions
As the registry lists them; a condition with its own page is linked.